Show Filters

Searches all publications.

Search Fulltext



Select publication to see the relevant sections.

Publication Date

    E.g., 2018-08-15
    E.g., 2018-08-15



1777 items
4:41 PM, Aug 03, 2018  |  BioCentury | Emerging Company Profile

Compass’ range

Compass Therapeutics LLC combines human cell display, high throughput antibody screening and a multispecific engineering platform to develop large libraries of cancer and autoimmune therapies. Traditional approaches to antibody discovery use hybridoma fusions in animals,...
12:11 PM, Jul 27, 2018  |  BioCentury | Emerging Company Profile

Wound-up bacteria

Ilya Pharma AB has engineered bacteria to produce a protein that promotes wound closure as a more convenient and lower cost alternative to recombinant protein therapies that accelerate wound healing. According to CEO Evelina Vågesjö,...
1:26 PM, Jul 20, 2018  |  BioCentury | Emerging Company Profile

Selective Regeneration

Surrozen Inc. is making tunable bispecific antibodies molecules it believes can overcome a major hurdle that has prevented other companies from tapping the Wnt pathway for regenerative medicine: namely, the inability to drug specific members...
1:03 PM, Jul 06, 2018  |  BioCentury | Emerging Company Profile

Tethering bleeding risk

With a mechanism that blocks thrombosis-contributing cells but not coagulation, Tetherex Pharmaceuticals Inc.’s pan-selectin inhibitor SelK2 could treat venous thromboembolism with little to no risk of bleeding. Chairman and CEO Scott Rollins said while antithrombotic drugs...
5:55 PM, Jun 22, 2018  |  BioCentury | Emerging Company Profile

Cerevance’s human element

Cerevance Inc. plans to treat neurological diseases by rebalancing disrupted neuronal circuits. The company is identifying circuit-specific neurological targets via its NETSeq RNA profiling platform, and thinks its ability to start with human tissue will...
9:27 AM, Jun 12, 2018  |  BioCentury | Emerging Company Profile

A Cancer Target Revolution

Revolution Medicines Inc. is developing inhibitors that target non-catalytic sites on proteins to block cell signaling pathways, such as Ras, that drive cancer cell proliferation. The company’s platform combines synthetic and medicinal chemistry, biochemistry, and structural...
3:11 PM, Jun 01, 2018  |  BioCentury | Emerging Company Profile

Scratching the surface

Oppilotech Ltd. is using computational modeling to develop first-in-class compounds that can permeate the lipopolysaccharide layer of the outer cell membrane of Gram-negative bacteria to potentiate existing antibiotics. Marketed polymyxins are used to disrupt the lipopolysaccharide...
12:54 PM, May 25, 2018  |  BioCentury | Emerging Company Profile

Universal ambitions

Emergex Vaccines Holdings Ltd. is making synthetic peptide vaccines it thinks could provide universal immunity -- and at a fraction of the time and cost of traditional vaccine development. Emergex launched in 2016 with IP acquired...
2:09 AM, May 18, 2018  |  BioCentury | Emerging Company Profile

Accent on RNA

With its debut Friday with a $40 million series A, Accent Therapeutics Inc. became the second disclosed newco to jump into the nascent arena of RNA epigenetics. The biotech has identified enzymes it believes drive...
1:39 PM, May 11, 2018  |  BioCentury | Emerging Company Profile

Enterin the gut

Enterin Inc. has a new twist on the longstanding Parkinson’s disease target alpha synuclein. The biotech is inhibiting the protein’s accumulation in intestinal nerves rather than in the brain, with the goal of treating constipation...